LLY - Eli Lilly and Company
The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook.
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 500 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum and is suitable for investors in the accumulation phase.
Dorsey Wright and Associates purchased a new stake in Eli Lilly and Company (NYSE: LLY) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 508 shares of the company's stock, valued at approximately $468,000. Other institutional investors and hedge funds have also recently modified their
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley will receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments u.
Lulu's Fashion Lounge Holdings (NASDAQ:LVLU) retained Solomon Partners as its financial advisor and Willkie Farr & Gallagher LLP as its legal advisor as the company evaluates strategic alternatives to maximize shareholder value. Alternatives may include a potential transaction or continued execution of Lulu's standalone strategic plan.
Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
For investors seeking to pare exposure to the artificial intelligence (AI) trade amid boom-induced volatility, shifting capital toward overlooked equities offers a compelling strategic alternative. Market participants are increasingly adopting a “defensive posture” against a possible downturn – pivoting to segments where high-quality operators with solid fundamentals have fallen out of favor leading to unwarranted valuation de-ratings.
Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reportedly neared an agreement to acquire a psychedelics company.
Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic compound 5-MeO-DMT developed by Beckley Psytech, the Oxford company founded by Amanda Feilding and her son Cosmo Feilding Mellen.
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has agreed to pay $6.75 a share in cash upfront ($2.8 billion) – with an additional $2.5 a share in contingent value rights (CVRs) tied to critical clinical and regulatory milestones.
CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026.
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion.
Eli Lilly and Co (NYSE:LLY) on Thursday agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal that values the clinical-stage mental health biotechnology company at up to approximately $3.8 billion, strengthening Lilly's portfolio of rapid-acting therapies for treatment-resistant depression and other psychiatric disorders.
A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000, and whether you capture the savings depends on a coverage question most people do not realize they are answering.
On CNBC's “Halftime Report Final Trades,” Bill Baruch, founder and CIO of both Blue Line Capital, an investment advisor, and Blue Creek Capital Management, named Eli Lilly and Company (NYSE:LLY) as his final trade.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio. Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.